{
    "nctId": "NCT01738152",
    "briefTitle": "Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health",
    "officialTitle": "A Single-Arm Clinical Trial Investigating the Feasibility of a Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Endometrial Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 106,
    "primaryOutcomeMeasure": "investigate feasibility of conducting a 12-week HLA treatment regimen",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* History of breast cancer or endometrial cancer confirmed at MSKCC or outside pathology report\n* Breast cancer patients must be at least 3 months post-active treatment (including chemotherapy, radiation therapy, endocrine therapy, and/or maintenance therapy), but not greater than 5 years post-active treatment (exception: AIs are required, and monoclonal antibodies are allowed)\n* Breast cancer patients must be currently on adjuvant aromatase inhibitors\n* Endometrial cancer patients must be at least 3 months post-active chemotherapy and/or maintenance therapy treatment but not greater than 5 years post-active chemotherapy and/or maintenance therapy treatment. They must be at least 4 weeks post-radiation therapy (EBRT or IVRT) but not greater than 5 years post-radiation therapy.\n* Endometrial cancer patients must have underwent surgical treatment (total abdominal hysterectomy (\\[TAH\\]/BSO)) and radiation therapy (external beam radiation therapy \\[EBRT\\] or IVRT)\n* Currently have no clinical evidence of disease\n* Menopausal at study entry as described by:\n* Surgical menopause (TAH/BSO), or\n* Age \u2265 50 years and cessation of menstruation for at least 1 year, or\n* Age \\<50 years and cessation of menstruation for at least 1 year with estradiol level in post-menopausal range, or\n* Rendered post-menopausal with the use of LHRH agonist\n* Patients who are new visits to Female Sexual Medicine Program or patients are not consistently using any vulvovaginal health promotion strategies (e.g., pelvic floor exercises, dilator therapy, moisturizers) recommended by the Female Sexual Medicine Program Reporting being bothered by vulvovaginal symptoms of estrogen deprivation (i.e., vulvovaginal dryness or discomfort \\[pain with intercourse or examination\\])\n* Without history of other cancers (excluding non-melanoma skin cancer)\n* Women at least 18 years of age\n* Able to read and speak English\n* Able to participate in the informed consent process\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Vaginal bleeding of unknown etiology within 12 months of study entry\n* Currently taking hormone replacement therapy \\[local or systemic\\] (Patients must discontinue for 2 weeks in order to be eligible prior to study enrollment)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}